Trial reportBreast cancer research and treatment2013
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA).
Trial report in Breast cancer research and treatment, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
Phase II Open-label, Multicentre, Randomized Trial of Neoadjuvant Palbociclib in Combination With Hormonal Therapy and HER2 Blockade Versus Paclitaxel in Combination With HER2 Blockade for Postmenopausal Patients With Hormone Receptor Positive/HER2 Positive Early Breast Cancer
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials.Frontiers in oncology · 2022Pooled it
- Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial.British journal of cancer · 2020Trial
- Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Trial
- Anti-Her2 therapy patterns in metastatic breast cancer-Real-world data suggest undertreatment.International journal of cancer · 2026Article
- Taste alterations in breast cancer patients undergoing chemotherapy: an observational study.Frontiers in nutrition · 2026Article
- Prospective Observational Study on Perioperative Dysgeusia and Trace Metal Elements in Patients Undergoing Pancreatoduodenectomy.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2025Article
- Cardiovascular Concerns, Cancer Treatment, and Biological and Chronological Aging in Cancer:JACC. CardioOncology · 2024Review
- Key Considerations for the Treatment of Advanced Breast Cancer in Older Adults: An Expert Consensus of the Canadian Treatment Landscape.Current oncology (Toronto, Ont.) · 2023Review
- Narrative Review of Multidisciplinary Management of Central Nervous Involvement in Patients with HER2-Positive Metastatic Breast Cancer: Focus on Elderly Patients.Advances in therapy · 2023Review
- Dysgeusia in Patients with Breast Cancer Treated with Chemotherapy-A Narrative Review.Nutrients · 2023Review
- Adverse Drug Reactions with HER2-Positive Breast Cancer Treatment: An Analysis from the Italian Pharmacovigilance Database.Drugs - real world outcomes · 2022Article
- Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients.Drugs & aging · 2021Review
- Comparison of outcomes in a population-based cohort of metastatic breast cancer patients receiving anti-HER2 therapy with clinical trial outcomes.Breast cancer research and treatment · 2020Article
- Article
- Expanding Therapeutic Options for Older Adults: Case-Based Updates in Breast and Lung Cancer.Journal of the American Geriatrics Society · 2019Review
- ＜Editors' Choice＞ Practice management for elderly patients with breast cancer; Findings from a survey by the Japan Breast Cancer Study Group.Nagoya journal of medical science · 2018Article
- Real-world treatment in patients with HER2+ metastatic breast cancer : Treatment decisions in HER2+ mBC.Breast cancer research and treatment · 2018Article
- Pharmacotherapeutic Management of Breast Cancer in Elderly Patients: The Promise of Novel Agents.Drugs & aging · 2018Review
- HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status.Oncotarget · 2016Article
- Twenty years of anti-HER2 therapy-associated cardiotoxicity.ESMO open · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 8 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the incidence of cancer increases with age, older patients are under-represented in cancer treatment trials, resulting in limited data availability in this patient population. Here we present results from pre-defined subgroup analyses conducted by age group (<65 vs ≥ 65 years) from a randomized, double-blind, placebo-controlled phase III trial in patients with HER2-positive metastatic breast cancer. Patients who had not received previous chemotherapy or biological therapy for HER2-positive locally recurrent, unresectable or metastatic breast cancer were randomly assigned to treatment with placebo, trastuzumab, and docetaxel or with pertuzumab, trastuzumab, and docetaxel. Primary endpoint was independently assessed progression-free survival. We performed pre-specified subgroup analyses of progression-free survival according to age. The study is registered with ClinicalTrials.gov, NCT00567190. 808 patients were enrolled. Of those, 127 patients were 65 years of age or older (placebo arm: 67, pertuzumab arm: 60). Patients in both age groups experienced progression-free survival benefit with treatment in the pertuzumab arm (<65 years: HR: 0.65; 95 % CI 0.53-0.80; ≥65 years: HR: 0.52; 95 % CI 0.31-0.86). Diarrhoea, fatigue, asthenia, decreased appetite, vomiting, and dysgeusia were reported more frequently in patients 65 years of age or older compared with younger patients. Neutropenia and febrile neutropenia were reported less frequently in the older age group. The efficacy and safety data reported in CLEOPATRA suggest that the combined use of pertuzumab, trastuzumab, and docetaxel should not be limited by patient age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.